Harmony Biosciences Holdings inc   (HRMY)
Other Ticker:  
Price: $32.1100 $0.01 0.031%
Day's High: $32.15 Week Perf: -1.11 %
Day's Low: $ 30.66 30 Day Perf: 1.81 %
Volume (M): 436 52 Wk High: $ 45.17
Volume (M$): $ 14,006 52 Wk Avg: $32.97
Open: $32.10 52 Wk Low: $18.61

 Market Capitalization (Millions $) 1,942
 Shares Outstanding (Millions) 60
 Employees 197
 Revenues (TTM) (Millions $) 582
 Net Income (TTM) (Millions $) 129
 Cash Flow (TTM) (Millions $) 67
 Capital Exp. (TTM) (Millions $) 0

Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc is a clinical-stage biopharmaceutical company that was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. The company is focused on developing and commercializing innovative therapies for patients with sleep and central nervous system disorders.

Harmony Biosciences Holdings Inc is primarily known for its lead product, WAKIXe (pitolisant), which was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations.

WAKIX represents a breakthrough in the treatment of narcolepsy as it works differently from existing treatments. It is a first-in-class medication that selectively targets the histamine 3 (H3) receptor, which is involved in the regulation of wakefulness and sleep. By activating this receptor, WAKIX increases histamine release in the brain, which helps to promote wakefulness.

Apart from WAKIX, Harmony Biosciences has a pipeline of other innovative compounds at various stages of development for central nervous system disorders. These include pitolisant, which is being evaluated for the treatment of patients with obstructive sleep apnea; and pitolisant-sodium oxybate, a combination therapy being developed for the treatment of narcolepsy.

Harmony Biosciences is also dedicated to bringing innovation and transformation to the field of sleep and central nervous system disorders. The company has a robust research and development program that is focused on identifying new molecular targets and developing new therapies to address unmet medical needs in the field.

In addition to developing innovative therapies, Harmony Biosciences is committed to improving the lives of patients with sleep and central nervous system disorders. The company collaborates with patient advocacy groups, healthcare professionals, and academic institutions to support research, education, and awareness of these disorders.

   Company Address: 630 W. Plymouth Meeting 19462 PA
   Company Phone Number: 539-9800   Stock Exchange / Ticker: NASDAQ HRMY


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc Surpasses Industry Averages with Impressive Revenue Growth in Latest Financial Report

Harmony Biosciences Holdings Inc has once again proven itself to be a leader in the pharmaceutical industry with its recent financial report for the fourth quarter of 2023. Despite a decrease in earnings per share compared to the previous year, the company saw a significant increase in revenue, demonstrating a continued commitment to growth and success.
One of the standout achievements from this report was the impressive revenue growth of 31.303%, far surpassing the industry average. This growth can be attributed to the company's focus on improving sales and meeting the demands of customers. Additionally, the increase in inventories and accounts receivable signal rising demand for Harmony Biosciences Holdings Inc's products, pointing towards a strong future for the company.


Harmony Biosciences Reports Robust Growth with WAKIX as Stock Struggles Short-Term

Published Tue, Oct 31 2023 11:30 AM UTC

In the recently released press statement, Harmony Biosciences Holdings Inc reported impressive financial results for the third quarter of 2023. The company's flagship product, WAKIX (pitolisant), achieved a net revenue of $160.3 million during this period, representing a significant increase of approximately 37% compared to the same quarter last year. Despite these...

Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc Surges in Revenue, but EPS Suffers a Setback in Third Quarter of 2023

Article: Harmony Biosciences Faces Challenges as Earnings Decline, but Revenue Rises
Harmony Biosciences Holdings Inc, a Major Pharmaceutical Preparations company, recently announced its financial results for the period of July to September 30, 2023. While the company saw a decline in earnings per share (EPS), it experienced an impressive rise in revenue. These results have significant implications for the company's future performance.
During the third quarter of 2023, Harmony Biosciences Holdings Inc reported earnings per share of $0.63 and revenue of $134.22 million. This represented a significant drop in EPS from $1.44 per share in the corresponding period the previous year. However, despite the decline in EPS, the company's revenue increased by a notable 36.488% in the same period. This revenue growth stands in contrast to the downward trend seen in many of its competitors in the Major Pharmaceutical Preparations industry during the matching period.

Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc Soars with an Exceptional 43.59% EPS Boost in Q2 2023, Shattering Industry Averages

Harmony Biosciences Holdings Inc, a major player in the Major Pharmaceutical Preparations industry, has announced impressive financial results for the period ending June 30, 2023. The company reported a remarkable 25.403% increase in revenue, reaching $134.22 million. Additionally, their profit per share rose by 43.59% to $0.56 per share, compared to the same period last year.
These substantial growth figures outperformed the overall industry, as major pharmaceutical preparations companies experienced a mere 3.69% increase in revenue during the same time frame. Moreover, Harmony Biosciences Holdings Inc witnessed a 16.67% growth in earnings per share, up from $0.48 per share, and a 12.667% rise in revenue.

Harmony Biosciences Holdings Inc

Robust 39.634% Top-line rise at HRMY during the financial time-frame ending March 31 2023

Harmony Biosciences Holdings Inc, a major pharmaceutical preparations company, achieved a return on average invested assets (ROI) of 34.45% in the first quarter of 2023. This ROI was above the company's average return on investment of 29.69%. However, ROI decreased compared to the previous quarter due to a decline in net income.
In the healthcare sector, 25 other companies had a higher ROI than Harmony Biosciences Holdings Inc. Additionally, the company's total ranking deteriorated from 107 to 120 in the most recent quarter.


Harmony Biosciences Holdings Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Harmony Biosciences Holdings Inc does not provide revenue guidance.

Earnings Outlook
Harmony Biosciences Holdings inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com